Gene Weaver

Gene Weaver is a preclinical-stage biotechnology company developing a programmable RNA-based gene insertion system.

Its enzymatic system enables targeted insertion of large DNA payloads at virtually any genomic site without introducing double-strand breaks, addressing key limitations of existing tools including variable site integration and restricted payload size.

The company received a $515,000 grant from the Bill and Melinda Gates Foundation in May 2025 to advance the technology toward gene therapy and affordable protein therapeutic manufacturing applications.